In the second half of the year, Phylogica expects to increase revenue, based on payments related to both existing and new agreements, whilst maintaining the current level of operating expenditure.
and
In the second half of FY2012, the Company aims to reach more milestones in its existing collaborations in addition to signing new partnerships with leading pharmaceutical or biotech companies.
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$1.36 |
Change
-0.035(2.51%) |
Mkt cap ! $793.2M | |||
| Open | High | Low | Value | Volume |
| $1.39 | $1.43 | $1.36 | $169.8K | 122.1K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 9675 | $1.36 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.45 | 2801 | 1 |
View Market Depth
| Last trade - 16.10pm 15/07/2025 (20 minute delay) ? |
| PYC (ASX) Chart |